Operational Costs Compared: SG&A Analysis of Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.

SG&A Trends: Amphastar vs. MiMedx Over a Decade

__timestamp	Amphastar Pharmaceuticals, Inc.	MiMedx Group, Inc.
Wednesday, January 1, 2014	40373000	90480000
Thursday, January 1, 2015	46974000	133384000
Friday, January 1, 2016	47298000	179997000
Sunday, January 1, 2017	50918000	220119000
Monday, January 1, 2018	58044000	258528000
Tuesday, January 1, 2019	63109000	198205000
Wednesday, January 1, 2020	65157000	181022000
Friday, January 1, 2021	68920000	198359000
Saturday, January 1, 2022	66592000	208789000
Sunday, January 1, 2023	80393000	211124000

Unveiling the hidden dimensions of data

A Decade of SG&A Trends: Amphastar vs. MiMedx

In the ever-evolving pharmaceutical landscape, operational efficiency is key. Over the past decade, Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc. have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amphastar's SG&A expenses grew by approximately 99%, reflecting a strategic expansion and investment in operational capabilities. In contrast, MiMedx's expenses surged by about 133%, indicating a more aggressive growth strategy.

Key Insights

Amphastar Pharmaceuticals: Starting at $40 million in 2014, their SG&A expenses reached $80 million by 2023, highlighting a steady growth pattern.
MiMedx Group: With a more volatile path, their expenses jumped from $90 million in 2014 to over $210 million in 2023, peaking in 2018.

These trends underscore the differing strategic priorities of these companies in a competitive market.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025

Similar Statistics

Selling, General, and Administrative Costs: Novo Nordisk A/S vs MiMedx Group, Inc.

Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared

SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.

Jazz Pharmaceuticals plc vs MiMedx Group, Inc.: SG&A Expense Trends

Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.

Comparing SG&A Expenses: Alkermes plc vs MiMedx Group, Inc. Trends and Insights

Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights

Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.

Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights

Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights

Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights

Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.